Remdesivir drug should only be used in patients with ‘moderate to severe’ COVID-19: HM

It also warned against the use of the drug in patients who are not on oxygen support or in home settings.

130
Medicine Injection drug vaccine Syringe
Picture: Pixabay

Last Updated on December 26, 2021 by The Health Master

The Centre on Friday said Remdesivir drug should only be used in patients with ‘moderate to severe’ COVID-19 and those with no renal or hepatic dysfunction within 10 days of the onset of any symptoms.

It also warned against the use of the drug in patients who are not on oxygen support or in home settings.

According to the clinical guidance issued by the Union health ministry for management of the infection in adult patients, Remdesivir has been asked to be “used in patients with moderate to severe COVID-19 and those with no renal or hepatic dysfunction within 10 days of the onset of any symptoms”.

The Tocilizumab drug may be considered for use in the presence of severe disease (preferably within 24 to 48 hours of onset of severe disease / ICU admission), according to the guidelines.

Tocilizumab can be used in case of significantly raised inflammatory markers (CRP &/or IL-6), condition not improving despite use of steroids and no active bacterial/fungal/tubercular infection.

The ministry also said that those over 60 years of age, with cardiovascular disease, hypertension, diabetes, and other immunocompromised states are at high risk for severe disease and mortality.

According to the guidelines, coronavirus patients have been classified into those affected by mild, moderate and severe disease.

For mild diseases, home isolation and care are recommended, while admission in a ward is recommended for those battling moderate diseases, and ICU has been recommended for patients with severe COVID-19, they added.

Tocilizumab

Favipiravir

Remdesivir

Amphotericin

Posaconazole

Schedule for 19 FDCs permitted pre-1988 to give online presentation

DCGI seeks more data from Serum Institute for Covovax Vaccine

Clinical Study for Itolizumab initiated in India

USFDA authorises first oral antiviral to treat COVID

Doctor couple booked for using restricted drug at hospital

IPC adds 15 new impurities Reference Substances and 11 IP Reference…

Drug alert: 22 out of 1102 samples declared as NSQ in…

Govt is able to collect data on only 237 Medical devices

Govt is working on policy to encourage research in Pharma sector

Haryana is the best state for setting up Pharma Industries: HM

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner